Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Continuation of the etonogestrel implant in women undergoing immediate postabortion placement.

Madden T, Eisenberg DL, Zhao Q, Buckel C, Secura GM, Peipert JF.

Obstet Gynecol. 2012 Nov;120(5):1053-9. doi: http://10.1097/AOG.0b013e3182632cd6.

2.

One-year continuation of the etonogestrel contraceptive implant in women with postabortion or interval placement.

Mark A, Sonalkar S, Borgatta L.

Contraception. 2013 Nov;88(5):619-23. doi: 10.1016/j.contraception.2013.05.009. Epub 2013 May 23.

PMID:
23790436
3.

The effect of immediate postpartum compared to delayed postpartum and interval etonogestrel contraceptive implant insertion on removal rates for bleeding.

Ireland LD, Goyal V, Raker CA, Murray A, Allen RH.

Contraception. 2014 Sep;90(3):253-8. doi: 10.1016/j.contraception.2014.05.010. Epub 2014 May 24.

PMID:
24973904
4.

Immediate postpartum etonogestrel implant: a contraception option with long-term continuation.

Wilson S, Tennant C, Sammel MD, Schreiber C.

Contraception. 2014 Sep;90(3):259-64. doi: 10.1016/j.contraception.2014.05.006. Epub 2014 May 14.

PMID:
24993485
5.

A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.

Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S; WHO Study Group on Contraceptive Implants for Women.

Hum Reprod. 2015 Nov;30(11):2527-38. doi: 10.1093/humrep/dev221. Epub 2015 Sep 25.

6.

Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.

Steinauer JE, Upadhyay UD, Sokoloff A, Harper CC, Diedrich JT, Drey EA.

Contraception. 2015 Dec;92(6):553-9. doi: 10.1016/j.contraception.2015.06.013. Epub 2015 Jun 17.

PMID:
26093190
7.

Immediate postabortion initiation of levonorgestrel implants reduces the incidence of births and abortions at 2 years and beyond.

Rose SB, Garrett SM, Stanley J.

Contraception. 2015 Jul;92(1):17-25. doi: 10.1016/j.contraception.2015.03.012. Epub 2015 Mar 27.

PMID:
25818594
8.

Comparison of contraceptive method chosen by women with and without a recent history of induced abortion.

Madden T, Secura GM, Allsworth JE, Peipert JF.

Contraception. 2011 Dec;84(6):571-7. doi: 10.1016/j.contraception.2011.03.018. Epub 2011 May 4.

9.

Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial.

Hubacher D, Spector H, Monteith C, Chen PL, Hart C.

Am J Obstet Gynecol. 2017 Feb;216(2):101-109. doi: 10.1016/j.ajog.2016.08.033. Epub 2016 Sep 20.

PMID:
27662799
10.

Intra-abortion contraception with etonogestrel subdermal implant.

Barros Pereira I, Carvalho RM, Graça LM.

Eur J Obstet Gynecol Reprod Biol. 2015 Feb;185:33-5. doi: 10.1016/j.ejogrb.2014.11.025. Epub 2014 Nov 29.

PMID:
25522115
11.

Contraceptive discontinuation and pregnancy postabortion in Nepal: a longitudinal cohort study.

Puri M, Henderson JT, Harper CC, Blum M, Joshi D, Rocca CH.

Contraception. 2015 Apr;91(4):301-7. doi: 10.1016/j.contraception.2014.12.011. Epub 2014 Dec 30.

PMID:
25553872
12.

Initiation and continuation of long-acting reversible contraception in the United States military healthcare system.

Chiles DP, Roberts TA, Klein DA.

Am J Obstet Gynecol. 2016 Sep;215(3):328.e1-9. doi: 10.1016/j.ajog.2016.03.027. Epub 2016 Mar 19.

PMID:
27005514
13.

Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women.

Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM.

Obstet Gynecol. 2012 Jul;120(1):21-6. doi: 10.1097/AOG.0b013e318259565a.

14.

Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant.

Flores JB, Balderas ML, Bonilla MC, Vázquez-Estrada L.

Int J Gynaecol Obstet. 2005 Sep;90(3):228-33.

PMID:
16043175
15.

Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.

McNicholas C, Swor E, Wan L, Peipert JF.

Am J Obstet Gynecol. 2017 Jun;216(6):586.e1-586.e6. doi: 10.1016/j.ajog.2017.01.036. Epub 2017 Jan 29.

PMID:
28147241
16.

Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.

Hognert H, Kopp Kallner H, Cameron S, Nyrelli C, Jawad I, Heller R, Aronsson A, Lindh I, Benson L, Gemzell-Danielsson K.

Hum Reprod. 2016 Nov;31(11):2484-2490. Epub 2016 Sep 22.

PMID:
27664217
17.

Postpartum contraception: initiation and effectiveness in a large universal healthcare system.

Brunson MR, Klein DA, Olsen CH, Weir LF, Roberts TA.

Am J Obstet Gynecol. 2017 Jul;217(1):55.e1-55.e9. doi: 10.1016/j.ajog.2017.02.036. Epub 2017 Feb 28.

PMID:
28257962
18.

Rapid repeat pregnancy in adolescents: do immediate postpartum contraceptive implants make a difference?

Tocce KM, Sheeder JL, Teal SB.

Am J Obstet Gynecol. 2012 Jun;206(6):481.e1-7. doi: 10.1016/j.ajog.2012.04.015. Epub 2012 Apr 16.

PMID:
22631865
19.

Bleeding related to etonogestrel subdermal implant in a US population.

Casey PM, Long ME, Marnach ML, Bury JE.

Contraception. 2011 May;83(5):426-30. doi: 10.1016/j.contraception.2010.09.012. Epub 2010 Nov 6.

PMID:
21477684
20.

Continuation rates of the subdermal contraceptive Implanon(®) and associated influencing factors.

Teunissen AM, Grimm B, Roumen FJ.

Eur J Contracept Reprod Health Care. 2014 Feb;19(1):15-21. doi: 10.3109/13625187.2013.862231. Epub 2013 Dec 13.

PMID:
24329119

Supplemental Content

Support Center